Welcome to our dedicated page for Caris Life Sciences news (Ticker: CAI), a resource for investors and traders seeking the latest updates and insights on Caris Life Sciences stock.
Caris Life Sciences, Inc. develops and commercializes AI-enabled precision medicine solutions built around comprehensive molecular profiling, next-generation sequencing and machine learning. The company’s diagnostics and data platform use Whole Genome, Whole Exome and Whole Transcriptome Sequencing, a multimodal clinico-genomic database and high-performance computing to support early detection, diagnosis, monitoring, therapy selection and drug development.
Company announcements commonly address molecular profiling services, clinical therapy selection volume, product launches and regulatory or reimbursement actions for tests such as Caris Assure, Caris MI Clarity and Caris ChromoSeq. Other recurring developments include peer-reviewed validation of Caris AI Insights, Caris Precision Oncology Alliance collaborations, conference presentations and quarterly financial results.
Caris Life Sciences (NASDAQ: CAI) launched Caris MI Clarity, an AI-powered prognostic test that predicts both early (0–5 years) and late (5–15 years) distant recurrence risk for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer at diagnosis. Results are typically returned within 3 business days. The model was trained on Caris' multimodal dataset and validated using samples from national trials including TAILORx and NSABP B-42. The test uses digitized H&E slides plus clinical inputs and does not require genomic sequencing, enabling scalability from routine pathology specimens.
Caris Life Sciences (NASDAQ: CAI) announced on May 4, 2026 that Caris ChromoSeq received MolDX approval, a Medicare molecular diagnostic review by Palmetto GBA that supports broader clinical access and potential reimbursement considerations for ultra‑deep whole genome tumor profiling in myeloid malignancies.
Caris ChromoSeq is described as the first ultra‑deep WGS assay for AML, MDS, MPN and related myeloid cancers, consolidating multiple tests into a single comprehensive report to aid diagnosis and treatment decisions.
Caris Life Sciences (NASDAQ: CAI) published a peer-reviewed study validating an AI-derived signature that predicts MGMT promoter methylation and temozolomide (TMZ) benefit in glioblastoma (GBM) patients.
The signature was developed from a clinico-genomic dataset of 5,841 patients and evaluated prospectively in >3,400 cases, showing high concordance with pyrosequencing and stratifying overall survival in TMZ-treated, IDH-wild type GBM.
Caris Life Sciences (NASDAQ: CAI) will present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference.
Presentations: May 12, 2026, 10:00–10:30 AM PT (BofA, Las Vegas) and June 8, 2026, 10:40–11:15 AM ET (Goldman Sachs, Miami). Live and replay webcasts will be available on the company investor relations website.
Caris Life Sciences (NASDAQ: CAI) announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. A live webcast will begin at 3:30 p.m. CT (4:30 p.m. ET) to discuss results, with a replay posted on the company investor relations website shortly after the call.
Caris Life Sciences (NASDAQ: CAI) announced on April 17, 2026 that the UCSF Helen Diller Family Comprehensive Cancer Center joined the Caris Precision Oncology Alliance (POA). The membership expands collaborative, biomarker-driven research using Caris' AI-driven multimodal database and comprehensive molecular profiling to support personalized cancer care.
Caris Life Sciences (NASDAQ: CAI) announced expansion of its Right-In-Time (RIT) clinical trial solution to bring biomarker-driven trials to community oncology sites nationwide.
The program spans >600 locations, 2,200 investigators and identified >71,000 patients for possible trial participation, using comprehensive WES/WTS/IHC profiling and a trial-matching workflow that can enroll patients in ~2 weeks (as few as 5 days).
Caris Life Sciences (NASDAQ: CAI) launched a multimodal AI-driven molecular signature to guide first-line treatment selection for a subset of PD-L1 ≥50% non-small cell lung cancer (NSCLC) patients.
The signature uses Whole Exome Sequencing, Whole Transcriptome Sequencing and clinical data via the proprietary CodeAI platform to predict which patients benefit from adding chemotherapy versus those harmed by it. Caris notes the insight is proprietary and available to Caris customers; the company previously received FDA approval in November 2024 for its WES/WTS tissue assay MI Cancer Seek.
Caris Life Sciences (NASDAQ: CAI) launched Caris ChromoSeq on April 2, 2026: a combined Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay for myeloid malignancies.
The test delivers ~250x genome read depth, 40 million transcriptome reads, supports bone marrow or peripheral blood samples, and has an expected seven-day turnaround.
Caris Life Sciences (NASDAQ: CAI) finalized Achieve 1 results for Caris Detect, a multi-cancer early detection test using Whole Genome Sequencing. The study enrolled 3,014 evaluable subjects and reported overall Stage I–II sensitivity ~60.3% and high specificities (asymptomatic 99.2%, benign/high-risk 96.0%). Stage-specific sensitivity ranged from 56.8% (Stage I) to 98.6% (Stage IV).
The company emphasized WGS superiority over methylation-only approaches and plans to add additional pillars, including Whole Transcriptome Sequencing, to improve performance.